174 related articles for article (PubMed ID: 35563171)
21. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.
Worthylake R; Opresko LK; Wiley HS
J Biol Chem; 1999 Mar; 274(13):8865-74. PubMed ID: 10085130
[TBL] [Abstract][Full Text] [Related]
22. Desmoglein 3 gene mediates epidermal growth factor/epidermal growth factor receptor signaling pathway involved in inflammatory response and immune function of anaphylactic rhinitis.
Ri H; Peiyan Z; Jianqi W; Yunteng Z; Gang L; Baoqing S
Biomed Pharmacother; 2019 Oct; 118():109214. PubMed ID: 31382129
[TBL] [Abstract][Full Text] [Related]
23. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo.
Richards KN; Zweidler-McKay PA; Van Roy N; Speleman F; Trevino J; Zage PE; Hughes DP
Cancer; 2010 Jul; 116(13):3233-43. PubMed ID: 20564646
[TBL] [Abstract][Full Text] [Related]
24. Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition.
Memarzadeh K; Savage DJ; Bean AJ
Cancer Biol Ther; 2019; 20(12):1416-1429. PubMed ID: 31475882
[TBL] [Abstract][Full Text] [Related]
25. The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6.
Menezes SV; Kovacevic Z; Richardson DR
J Biol Chem; 2019 Mar; 294(11):4045-4064. PubMed ID: 30679310
[TBL] [Abstract][Full Text] [Related]
26. Lysosomal ATP Transporter SLC17A9 Controls Cell Viability via Regulating Cathepsin D.
Huang P; Cao Q; Xu M; Dong XP
Cells; 2022 Mar; 11(5):. PubMed ID: 35269509
[TBL] [Abstract][Full Text] [Related]
27. UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.
Zage PE; Sirisaengtaksin N; Liu Y; Gireud M; Brown BS; Palla S; Richards KN; Hughes DP; Bean AJ
Cancer; 2013 Feb; 119(4):915-23. PubMed ID: 22990745
[TBL] [Abstract][Full Text] [Related]
28. Interaction between SCP3 and JAB1 Confers Cancer Therapeutic Resistance and Stem-like Properties through EGF Expression.
Oh SJ; Noh KH; Song KH; Kim TW
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445562
[TBL] [Abstract][Full Text] [Related]
29. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor.
Ho R; Minturn JE; Hishiki T; Zhao H; Wang Q; Cnaan A; Maris J; Evans AE; Brodeur GM
Cancer Res; 2005 Nov; 65(21):9868-75. PubMed ID: 16267010
[TBL] [Abstract][Full Text] [Related]
30. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
[TBL] [Abstract][Full Text] [Related]
31. MGL S3 Chimeric Enzyme Drives Apoptotic Death of EGFR-Dependent Cancer Cells through ERK Downregulation.
Bondarev N; Ivanenko K; Khabusheva E; Lebedev T; Manukhov I; Prassolov V
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361596
[TBL] [Abstract][Full Text] [Related]
32. Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells.
Zang Y; Beard RL; Chandraratna RA; Kang JX
Cell Death Differ; 2001 May; 8(5):477-85. PubMed ID: 11423908
[TBL] [Abstract][Full Text] [Related]
33. Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients.
Valdez C; Wong YC; Schwake M; Bu G; Wszolek ZK; Krainc D
Hum Mol Genet; 2017 Dec; 26(24):4861-4872. PubMed ID: 29036611
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells.
Glogowska A; Stetefeld J; Weber E; Ghavami S; Hoang-Vu C; Klonisch T
Neoplasia; 2012 May; 14(5):396-409. PubMed ID: 22745586
[TBL] [Abstract][Full Text] [Related]
35. Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling.
Hasegawa Y; Takahashi M; Ariki S; Asakawa D; Tajiri M; Wada Y; Yamaguchi Y; Nishitani C; Takamiya R; Saito A; Uehara Y; Hashimoto J; Kurimura Y; Takahashi H; Kuroki Y
Oncogene; 2015 Feb; 34(7):838-45. PubMed ID: 24608429
[TBL] [Abstract][Full Text] [Related]
36. Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status.
Sacks NP; Smith K; Norman AP; Greenall M; LeJeune S; Harris AL
Eur J Cancer; 1993; 29A(3):426-8. PubMed ID: 8398346
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal gene therapy restores the autophagy-lysosomal pathway and attenuates retinal degeneration in cathepsin D-deficient mice.
Liu J; Bassal M; Schlichting S; Braren I; Di Spiezio A; Saftig P; Bartsch U
Neurobiol Dis; 2022 Mar; 164():105628. PubMed ID: 35033660
[TBL] [Abstract][Full Text] [Related]
38. Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling.
Ketterer S; Mitschke J; Ketscher A; Schlimpert M; Reichardt W; Baeuerle N; Hess ME; Metzger P; Boerries M; Peters C; Kammerer B; Brummer T; Steinberg F; Reinheckel T
Nat Commun; 2020 Oct; 11(1):5133. PubMed ID: 33046706
[TBL] [Abstract][Full Text] [Related]
39. Lowering Endogenous Cathepsin D Abundance Results in Reactive Oxygen Species Accumulation and Cell Senescence.
Su S; Zhu X; Lin L; Chen X; Wang Y; Zi J; Dong Y; Xie Y; Zhu Y; Zhang J; Zhu J; Xu D; Xu N; Lou X; Liu S
Mol Cell Proteomics; 2017 Jul; 16(7):1217-1232. PubMed ID: 26657266
[TBL] [Abstract][Full Text] [Related]
40. Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells.
Bach AS; Derocq D; Laurent-Matha V; Montcourrier P; Sebti S; Orsetti B; Theillet C; Gongora C; Pattingre S; Ibing E; Roger P; Linares LK; Reinheckel T; Meurice G; Kaiser FJ; Gespach C; Liaudet-Coopman E
Oncotarget; 2015 Sep; 6(29):28084-103. PubMed ID: 26183398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
